Marc Carrier: Proud to Share the Results of the WAVe Study
Marc Carrier, Professor at Ottawa Hospital Research Institute, shared on LinkedIn:
”Proud to share the results of the WAVe Study published in AjHematology
In this Canadian multicenter collaboration across six academic centers, we evaluated weight-adjusted dalteparin dosing (up to 33,000 IU/day) in patients with cancer-associated thrombosis weighing >90 kg.
Despite early study termination due to recruitment challenges — following the rapid uptake of DOACs for VTE and updated ISTH guidance removing the upper weight limit for DOAC use — our findings remain clinically relevant:
- Major bleeding: 5.3% at 30 days
- Recurrent VTE: 1.2% at 30 days
- No significant drug accumulation (based on anti-Xa levels)
These results suggest that weight-adjusted LMWH remains a safe and effective option for selected patients with cancer and obesity, particularly those at higher bleeding risk or with contraindications to DOACs.”
Read the full article here.
Article: A Multicenter Prospective Cohort Study on the Use of Weight-Adjusted Dalteparin in Patients Over 90 kg With Acute Cancer-Associated Venous Thromboembolism—The WAVe Study
Authors: Tzu-Fei Wang, Erik Yeo, Peter L. Gross, Chantal Séguin, Cynthia Wu, Sudeep Shivakumar, Ranjeeta Mallick, Aurélien Delluc, Julien D’Astous, Miriam Kimpton, Guillaume Roberge, Deborah M. Siegal, Tobias Tritschler, Grégoire Le Gal, Marc Carrier
Stay updated on all scientific advances with Hemostasis Today.
-
Jul 2, 2026, 19:40Minoo Ahmadinejad: Improving the Recognition of Women and Girls With Hemophilia
-
Jul 2, 2026, 19:26Dhinesh Selvaraju: FDA Expands Access to HYMPAVZI in Hemophilia
-
Jul 2, 2026, 19:13Syed Fahad Hussain: Not Every Low Platelet Count Tells the Same Story
-
Jul 2, 2026, 18:59Indu Thakur: Supporting Blood Donation Through Public Awareness in MSBT
-
Jul 2, 2026, 18:47Vee Townsend: IMHUE Highlights 9 Myths and Facts About Hemophilia B
-
Jul 2, 2026, 17:17Nico Gagelmann: Launching Myths and Facts on Hematology and Cell Therapy
-
Jul 2, 2026, 17:05Haroun Gajraj: Understanding the Technology Behind Spider Vein Treatment
-
Jul 2, 2026, 16:44Ney Carter Borges: Is It Time to Personalize Antiplatelet Therapy?
-
Jul 2, 2026, 16:22Introducing a New Resource for the ITP Community – ITP Support Association